cabalettabio.comCrawled Oct 24, 2026
Cabaletta Bio’s engineered T cell therapy leverages natural cell-killing capabilities through the CABA Platform and CARTA/CAART approaches.
CABA-201, a CD19-CAR T cell therapy, is Cabaletta Bio’s lead candidate for severe autoimmune diseases.
The page describes Cabaletta Bio’s engineered T cell therapy candidates and pipeline, including the DesCAARTes trial.
The page targets patients with autoimmune diseases, detailing B cell-mediated conditions, technology, and a Phase 1 trial.
The page highlights research publications and posters on B cell-mediated autoimmune cell therapy and clinical trials.
The corporate investor presentation outlines Cabaletta Bio’s mission for targeted cellular therapies in autoimmune diseases.
The page lists past Cabaletta Bio events, conferences, and participation history.
The page shares Cabaletta Bio news, press releases, and financial updates on cell and gene therapy developments.
Cabaletta Bio seeks talent to develop cures for autoimmune diseases.
Cabaletta Bio’s Board of Directors supports bringing targeted cell therapy to patients with autoimmune diseases.
The leadership team at Cabaletta Bio drives development of targeted cell therapy for B cell-mediated autoimmune diseases.
The scientific advisory board at Cabaletta Bio aids in advancing cell therapy for B-cell mediated autoimmune diseases.
Cabaletta Bio aims to cure patients with B cell-mediated autoimmune diseases.
Cabaletta Bio collaborates with academic and corporate partners to advance cell therapy development and clinical studies.
Cabaletta Bio (Nasdaq: CABA) develops targeted cell therapies for autoimmune diseases using the CABA platform, including CARTA (Chimeric Anti
Cabaletta Bio partners in Philadelphia and engages with the community through the getREAL program.
Cabaletta Bio offers information on its cell therapy product candidates for autoimmune diseases.
Anup Marda Chief Financial Officer investors@cabalettabio.com
Cabaletta Bio discovers and develops targeted cell therapy candidates for autoimmune diseases, including CAAR T cell products.
The Terms of Use govern access and usage of the Cabaletta Bio website.